Journal of Controlled Release Submission Process

The searcher job here is procedural: what happens after the author starts the Elsevier record, what can delay the file, what the first editor screen tests, and how to interpret the decision path. It is not a broad verdict on whether JCR is the best target.

Use the split this way:

The boundary matters because JCR process intent is narrower than broad submission intent. This page assumes the author has already chosen JCR and now needs the generated record to show controlled release as the scientific contribution, not merely as a formulation performance label.

These figures are journal-level ScienceDirect insights, not promises for one manuscript. The 6-day first-decision number mostly tells authors that JCR has a fast early screen. It does not mean a paper sent to reviewers has completed peer review in six days.

Use 6 days as the early-screen planning point. Use 30 to 103 days for complex or delayed externally reviewed cases when reviewer matching depends on release mechanism, formulation science, pharmacokinetics, biodistribution, nanomedicine, biomaterials, vaccine delivery, gene delivery, barrier transport, or in vivo translational evidence.

The calibrated range is straightforward. Administrative returns and desk-screen decisions can happen quickly, while externally reviewed delivery-science papers can take longer when reviewer matching spans chemistry, pharmaceutics, biomaterials, nanomedicine, PK/PD, animal models, and translational pharmacology.

Elsevier Editorial Manager can delay the record before a scientific editor evaluates the contribution. Routine checks include authorship, competing interests, ethics approval, consent where relevant, animal-study compliance, permissions, plagiarism screening readiness, reporting or data-policy material, figure integrity, table completeness, supplementary files, data availability, and declaration statements.

For JCR, an early return can also expose a process-positioning problem. Your Paper Your Way reduces formatting friction, but it does not remove the need for a reviewable scientific package. A single PDF can be acceptable for refereeing and still be editorially weak if the release mechanism, biological context, or translational evidence is buried or missing.

The first 48 hours should not ask the editor to reconcile mismatched artifacts:

• the abstract should name the release-control problem, delivery system, biological context, and central evidence
• Highlights should explain mechanism and evidence, not only material novelty or encapsulation performance
• figures should connect formulation, release behavior, and biological or translational effect
• methods should show release conditions, model relevance, biological assays, animal or ex vivo rationale, and statistical treatment
• the cover letter should explain why the delivery mechanism is central enough for JCR

These are process issues because the editor sees the generated record, not the author's private intent. If the record makes formulation properties louder than controlled-release mechanism, JCR triage becomes harder.

The editor's first screen asks whether the paper is genuinely a Journal of Controlled Release paper.

Three tests matter most:

1. Release-mechanism primacy. Does the manuscript explain how the carrier, matrix, polymer, hydrogel, depot, nanoparticle, device, conjugate, or system controls release or localization?
2. Evidence ladder. Do the release curves, characterization, biological assays, in vivo or ex vivo evidence, and claim level support each other?
3. JCR conversation fit. Does the paper join delivery science rather than materials chemistry, formulation screening, drug discovery, pharmacology, or biomaterials as the primary contribution?

A fast first decision should be read as a screen signal. It can mean the record was returned administratively, the manuscript did not sit inside JCR's aims and scope, or the editor did not see enough release-mechanism contribution to justify reviewers. It should not be read as proof that every JCR decision happens in six days.

The strongest process package makes the first screen easy. The title names the delivery object. The abstract identifies the release mechanism. The first figure connects design, release behavior, and biological context. The methods justify the release conditions and model. The discussion explains what changes for delivery science, not only what formulation performed better.

Once a JCR manuscript clears the first screen, reviewer selection follows the delivery mechanism and claim level rather than the material label alone. The Guide for Authors describes JCR as using a single-anonymized review process, effectively the single-blind model for authors: reviewers can see author identity, while authors do not know reviewer identity unless the reviewer chooses otherwise.

Reviewer routing often depends on:

• formulation and polymer-science reviewers when the carrier, matrix, hydrogel, depot, or material architecture controls release
• pharmacokinetics, biodistribution, toxicity, or in vivo reviewers when therapeutic or translational claims are central
• nanomedicine, vaccine-delivery, gene-delivery, biologics, or barrier-transport reviewers when the system works through a specialized delivery route
• biomaterials or device reviewers when the delivery mechanism depends on scaffold, implant, coating, depot, or interface behavior
• method reviewers when release kinetics, model selection, animal design, statistics, or reproducibility carries the claim

The response from review usually turns on whether the process package made the release claim auditable. A manuscript can be technically complete and still receive a difficult decision if reviewers decide the mechanism is descriptive, release conditions are not biologically relevant, in vivo support is too thin, the claim is overstated, or the work belongs in a neighboring journal.

The current public source layer gives authors four useful process signals:

The process consequence is practical. Authors should not treat JCR as a general pharmaceutics upload where any formulation with release data belongs. The generated record has to show why release control or delivery science is the protagonist.

Current ScienceDirect article surfaces show why the process record has to make the delivery mechanism explicit. Recent JCR examples include targeted nanoparticle delivery of irinotecan with PD-L1 blockade in colorectal cancer (10.1016/j.jconrel.2026.114609), compacted solid implant formulations for long-term buprenorphine delivery (10.1016/j.jconrel.2026.114722), a multidomain peptide-liposome composite for controlled release of a cyclic dinucleotide in oral cancer (10.1016/j.jconrel.2026.114730), co-delivery of a STING agonist and IDO1 blockade (10.1016/j.jconrel.2026.114731), extrahepatic lipid nanoparticle screening for in vivo mRNA targeting (10.1016/j.jconrel.2026.114728), and clinically relevant iron oxide nanoparticles affecting macrophage polarization and tumor microenvironment modulation (10.1016/j.jconrel.2026.114726).

Those examples do not dictate a formula, but they calibrate the process package. JCR submissions are strongest when the main record connects delivery design, release behavior, biological context, and claim level. A formulation that only reports size, loading, and release percentage is hard to triage. A record that shows how the system changes delivery, targeting, residence time, immune response, biodistribution, tissue penetration, or therapeutic window gives the editor a clearer reason to send it to reviewers.

Use those examples as an upload-readiness test:

In our pre-submission review work with Journal of Controlled Release manuscripts, we read the Editorial Manager package as one connected delivery-science record: title, abstract, Highlights, graphical logic, release profiles, characterization, biological model, in vivo or ex vivo evidence, data statement, supplementary files, and journal-routing logic. A paper can be uploadable and still process-weak if those components make the editor reconstruct why the work is controlled release.

Formulation properties without release mechanism. The manuscript reports particle size, loading efficiency, morphology, encapsulation, and short in vitro release, but the release-control decision is not named. The editor sees formulation characterization, not delivery science.

Translational claim ahead of evidence. The abstract or cover letter claims therapeutic, targeting, toxicity-reduction, pharmacokinetic, or biodistribution significance from release curves and cell assays alone. The evidence ladder is too short for the claim.

Review proposal not separated. Review submissions can fail process clarity when the author uploads a normal review manuscript without a distinct Review Proposal file explaining why the topic matters to JCR readership and drug-delivery science.

Neighboring-venue confusion. The work may be stronger for International Journal of Pharmaceutics, Biomaterials, Acta Biomaterialia, Molecular Pharmaceutics, Pharmaceutics, or Advanced Drug Delivery Reviews if the center is formulation completeness, biomaterial function, synthesis, or broad review synthesis rather than JCR delivery mechanism.

These patterns are process-relevant because JCR editors see the generated record, not the author's private explanation. In our checks, the weak package usually has good formulation work but a vague delivery claim. The title says controlled release, but the abstract reports a material and a payload. The Highlights repeat encapsulation efficiency or particle size. The first figure shows synthesis or morphology, while the release mechanism appears late. The biological model is described as proof of therapeutic relevance even when it only supports compatibility or short-term activity. The supplement carries release conditions, secondary controls, and raw profiles that should have been visible in the main review file.

The stronger package makes the release mechanism, biological model, translational boundary, and route fit visible in the abstract, figures, release data, and limitations before reviewers are invited. The first page names the delivery problem. The main figure shows the carrier or device, release trigger or control logic, and biological context. Release profiles are tied to conditions a reviewer can judge. The biological evidence supports the exact claim being made, not a broader therapeutic promise. If the manuscript is a review, the Review Proposal file explains why the topic matters to JCR readership instead of treating the review manuscript alone as enough.

That is why our process review reads the upload as an editor-facing artifact, not a formatting bundle. Your Paper Your Way is useful because it avoids premature layout work. It is dangerous only when authors treat it as permission to send an under-assembled scientific record. The editor still needs a clear release mechanism, evidence ladder, and venue rationale before spending reviewer capacity.

Watch for these named process failures before uploading:

• Controlled release as a label. The manuscript uses "controlled release" language but does not explain the release-control mechanism.
• In vitro-only overclaim. Release curves and cell assays are used to support therapeutic, biodistribution, or translational claims that need stronger biological evidence.
• Your Paper Your Way complacency. Authors use flexible formatting as a reason to submit an incomplete or hard-to-review evidence package.
• Review proposal gap. A review article lacks the separate Review Proposal file that JCR requests in Editorial Manager.
• Wrong neighboring venue. The contribution is mainly formulation, biomaterial chemistry, drug discovery, or broad review synthesis rather than delivery mechanism.

Check whether your JCR record proves a release mechanism →

Check whether your translational claim matches the evidence ladder →

Check whether your JCR package is ready for Editorial Manager →

JCR decisions are easier to interpret if you separate process, fit, evidence, and peer-review outcome.

The important distinction is between "fix the record" and "change the paper." A missing Review Proposal file is a process repair. A decision saying the work is formulation screening with weak mechanism is a manuscript-positioning problem.

Method note: we reviewed the official ScienceDirect Journal of Controlled Release journal page, ScienceDirect Guide for Authors, ScienceDirect insights page, Controlled Release Society journal description, existing Manusights JCR fit owner, and adjacent drug-delivery venue owners before creating this process page. Source limitation: ScienceDirect provides current journal-level timing and author-process details, but it does not publish a stable desk-rejection rate by drug-delivery subfield.

The evidence boundary is deliberate. Official Elsevier and society materials establish the journal source, scope, Editorial Manager route, Your Paper Your Way process, review-proposal requirement, author-package expectations, indexing/timing insights, and publication workflow. Manusights adds the author-side process layer: whether the generated record makes the release mechanism, evidence ladder, biological model, review-proposal artifact, and venue choice obvious before the editor spends reviewer capacity.

Use this page for the judgment layer, not as a substitute portal. ScienceDirect remains the source for mandatory current fields. The Manusights contribution is the JCR-specific interpretation of what those fields need to show when the manuscript is trying to look like delivery science rather than a generic formulation report.

Last verified: July 17, 2026 against ScienceDirect, Editorial Manager, and Controlled Release Society source URLs.